A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells

• Published in: International journal of molecular sciences 2017-02, Vol.18 (2), p.401-401
• Main Authors: Serwotka-Suszczak, Anna M, Sochaj-Gregorczyk, Alicja M, Pieczykolan, Jerzy, Krowarsch, Daniel, Jelen, Filip, Otlewski, Jacek
• Format: Article
• Language: English
• Subjects: Amino acid sequence; Aminobenzoates - chemistry; Aminobenzoates - pharmacology; Animals; Antibodies, Monoclonal - chemistry; Antibodies, Monoclonal - isolation & purification; Antibodies, Monoclonal - pharmacology; Antibody Specificity; Cancer; Cell Line, Tumor; Cell Survival - drug effects; Communication; Conjugates; Conjugation; Cytotoxicity; diaffibody; Disease Models, Animal; Drug carriers; Drug delivery; Epidermal growth factor; ErbB-2 protein; Escherichia coli; Flow cytometry; Growth factors; HER2; Humans; Immunoconjugates - chemistry; Immunoconjugates - pharmacology; Molecular Targeted Therapy; Monoclonal antibodies; monomethyl auristatin E (MMAE); Neoplasms - drug therapy; Neoplasms - metabolism; Neoplasms - pathology; Oligopeptides - chemistry; Oligopeptides - pharmacology; Protein Binding; Protein Stability; Receptor, ErbB-2 - antagonists & inhibitors; Receptor, ErbB-2 - metabolism; Surface plasmon resonance; targeted therapy; Thermodynamics; Tumor cells; Xenograft Model Antitumor Assays
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms18020401

Antibody-drug conjugates (ADCs) have recently emerged as efficient and selective cancer treatment therapeutics. Currently, alternative forms of drug carriers that can replace monoclonal antibodies are under intensive investigation. Here, a cytotoxic conjugate of an anti-HER2 (Human Epidermal Growth Factor Receptor 2) diaffibody with monomethyl-auristatin E (MMAE) is proposed as a potential anticancer therapeutic. The anti-HER2 diaffibody was based on the Z affibody amino acid sequence. The anti-HER2 diaffibody has been expressed as a His-tagged protein in and purified by Ni-nitrilotriacetyl (Ni-NTA) agarose chromatography. The molecule was properly folded, and the high affinity and specificity of its interaction with HER2 was confirmed by surface plasmon resonance (SPR) and flow cytometry, respectively. The (Z )₂DCS-MMAE conjugate was obtained by coupling the maleimide group linked with MMAE to cysteines, which were introduced in a drug conjugation sequence (DCS). Cytotoxicity of the conjugate was evaluated using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2- -tetrazolium bromide MTT assay and the xCELLigence Real-Time Cell Analyzer. Our experiments demonstrated that the conjugate delivered auristatin E specifically to HER2-positive tumor cells, which finally led to their death. These results indicate that the cytotoxic diaffibody conjugate is a highly potent molecule for the treatment of various types of cancer overexpressing HER2 receptors.